tiprankstipranks
Tandem Diabetes Care (GB:0M0F)
LSE:0M0F
UK Market
0M0F
Tandem Diabetes Care
RESEARCH TOOLSreports

Tandem Diabetes Care (0M0F) Share Forecast & Price Target

6 Followers
See the Price Targets and Ratings of:

0M0F Analyst Ratings

Moderate Buy
16Ratings
Moderate Buy
9 Buy
7 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Tandem
Diabetes Care
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0M0F Stock 12 Month Forecast

Average Price Target

$26.50
▲(59.16% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is $26.50 with a high forecast of $50.00 and a low forecast of $15.50. The average price target represents a 59.16% change from the last price of $16.65.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","21":"$21","31":"$31","41":"$41","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,21,31,41,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.27,21.633846153846154,23.997692307692308,26.36153846153846,28.725384615384613,31.089230769230767,33.45307692307692,35.816923076923075,38.18076923076923,40.54461538461538,42.90846153846154,45.27230769230769,47.636153846153846,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.27,19.826153846153847,20.38230769230769,20.93846153846154,21.494615384615386,22.05076923076923,22.606923076923078,23.163076923076922,23.71923076923077,24.275384615384617,24.83153846153846,25.38769230769231,25.943846153846152,{"y":26.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.27,18.98,18.69,18.4,18.11,17.82,17.53,17.24,16.95,16.66,16.37,16.08,15.79,{"y":15.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.638,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.33,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.027,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.272,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.199,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.61,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.974,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.45,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.36,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.27,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$26.50Lowest Price Target$15.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on GB:0M0F
Steven Lichtman
William Blair
William Blair
―
Buy
―
Initiated
08/21/26
Tandem Diabetes initiated with an Outperform at William BlairTandem Diabetes initiated with an Outperform at William Blair
Citi Analyst forecast on GB:0M0F
Joanne Wuensch
Citi
Citi
$21→$24
Hold
44.14%
Upside
Reiterated
08/14/26
Citi Sticks to Its Hold Rating for Tandem Diabetes Care (TNDM)
Canaccord Genuity Analyst forecast on GB:0M0F
William Plovanic
Canaccord Genuity
Canaccord Genuity
$40
Buy
140.24%
Upside
Reiterated
08/11/26
Tandem Diabetes Care: Buy Rating Reaffirmed on Transformation Momentum and Innovation Catalysts; $40 Price Target Maintained
Oppenheimer Analyst forecast on GB:0M0F
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
$22
Buy
32.13%
Upside
Assigned
08/07/26
Oppenheimer Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)
Truist Financial Analyst forecast on GB:0M0F
Richard Newitter
Truist Financial
Truist Financial
$31
Buy
86.19%
Upside
Reiterated
08/07/26
Analysts' Top NA Picks: StandardAero, Inc. (SARO), Tandem Diabetes Care (TNDM)
Stifel Nicolaus Analyst forecast on GB:0M0F
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$22
Hold
32.13%
Upside
Reiterated
08/07/26
Stifel Nicolaus Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)
Bank of America Securities Analyst forecast on GB:0M0F
Travis Steed
Bank of America Securities
Bank of America Securities
$25
Hold
50.15%
Upside
Reiterated
08/07/26
Analysts Offer Insights on NA Companies: Springer Nature AG & Co. KGaA (Other OTC: SPGDF), Lionsgate Studios (NYSE: LION) and Tandem Diabetes Care (NASDAQ: TNDM)
Lake Street Analyst forecast on GB:0M0F
Frank Takkinen
Lake Street
Lake Street
$50
Buy
200.30%
Upside
Reiterated
08/07/26
Tandem Diabetes Care (TNDM) Receives a Buy from Lake Street
UBS Analyst forecast on GB:0M0F
Patrick Wood
UBS
UBS
$18
Hold
8.11%
Upside
Reiterated
08/07/26
UBS Keeps Their Hold Rating on Tandem Diabetes Care (TNDM)
Piper Sandler Analyst forecast on GB:0M0F
Matthew O'Brien
Piper Sandler
Piper Sandler
$33
Buy
98.20%
Upside
Reiterated
08/07/26
Tandem Diabetes Care (TNDM) Gets a Buy from Piper Sandler
TD Cowen Analyst forecast on GB:0M0F
Mathew Blackman
TD Cowen
TD Cowen
$28
Buy
68.17%
Upside
Reiterated
08/06/26
Analyst Reiterates Buy on Tandem, Citing Building Momentum Ahead of Mobi Tubeless Launch and Improving Margins
RBC Capital Analyst forecast on GB:0M0F
Kendall Au
RBC Capital
RBC Capital
$30→$26
Buy
56.16%
Upside
Reiterated
08/06/26
RBC Capital Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
Mizuho Securities Analyst forecast on GB:0M0F
Anthony Petrone
Mizuho Securities
Mizuho Securities
$24→$20
Hold
20.12%
Upside
Reiterated
07/15/26
Tandem Diabetes price target lowered to $20 from $24 at MizuhoTandem Diabetes price target lowered to $20 from $24 at Mizuho
Goldman Sachs Analyst forecast on GB:0M0F
David Roman
Goldman Sachs
Goldman Sachs
$21→$16
Hold
-3.90%
Downside
Reiterated
07/14/26
Tandem Diabetes Care (TNDM) Gets a Hold from Goldman Sachs
Deutsche Bank Analyst forecast on GB:0M0F
Kieran Ryan
Deutsche Bank
Not Ranked
Deutsche Bank
$15.5
Hold
-6.91%
Downside
Initiated
06/23/26
Tandem Diabetes initiated with a Hold at Deutsche BankTandem Diabetes initiated with a Hold at Deutsche Bank
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on GB:0M0F
Steven Lichtman
William Blair
William Blair
―
Buy
―
Initiated
08/21/26
Tandem Diabetes initiated with an Outperform at William BlairTandem Diabetes initiated with an Outperform at William Blair
Citi Analyst forecast on GB:0M0F
Joanne Wuensch
Citi
Citi
$21→$24
Hold
44.14%
Upside
Reiterated
08/14/26
Citi Sticks to Its Hold Rating for Tandem Diabetes Care (TNDM)
Canaccord Genuity Analyst forecast on GB:0M0F
William Plovanic
Canaccord Genuity
Canaccord Genuity
$40
Buy
140.24%
Upside
Reiterated
08/11/26
Tandem Diabetes Care: Buy Rating Reaffirmed on Transformation Momentum and Innovation Catalysts; $40 Price Target Maintained
Oppenheimer Analyst forecast on GB:0M0F
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
$22
Buy
32.13%
Upside
Assigned
08/07/26
Oppenheimer Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)
Truist Financial Analyst forecast on GB:0M0F
Richard Newitter
Truist Financial
Truist Financial
$31
Buy
86.19%
Upside
Reiterated
08/07/26
Analysts' Top NA Picks: StandardAero, Inc. (SARO), Tandem Diabetes Care (TNDM)
Stifel Nicolaus Analyst forecast on GB:0M0F
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$22
Hold
32.13%
Upside
Reiterated
08/07/26
Stifel Nicolaus Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)
Bank of America Securities Analyst forecast on GB:0M0F
Travis Steed
Bank of America Securities
Bank of America Securities
$25
Hold
50.15%
Upside
Reiterated
08/07/26
Analysts Offer Insights on NA Companies: Springer Nature AG & Co. KGaA (Other OTC: SPGDF), Lionsgate Studios (NYSE: LION) and Tandem Diabetes Care (NASDAQ: TNDM)
Lake Street Analyst forecast on GB:0M0F
Frank Takkinen
Lake Street
Lake Street
$50
Buy
200.30%
Upside
Reiterated
08/07/26
Tandem Diabetes Care (TNDM) Receives a Buy from Lake Street
UBS Analyst forecast on GB:0M0F
Patrick Wood
UBS
UBS
$18
Hold
8.11%
Upside
Reiterated
08/07/26
UBS Keeps Their Hold Rating on Tandem Diabetes Care (TNDM)
Piper Sandler Analyst forecast on GB:0M0F
Matthew O'Brien
Piper Sandler
Piper Sandler
$33
Buy
98.20%
Upside
Reiterated
08/07/26
Tandem Diabetes Care (TNDM) Gets a Buy from Piper Sandler
TD Cowen Analyst forecast on GB:0M0F
Mathew Blackman
TD Cowen
TD Cowen
$28
Buy
68.17%
Upside
Reiterated
08/06/26
Analyst Reiterates Buy on Tandem, Citing Building Momentum Ahead of Mobi Tubeless Launch and Improving Margins
RBC Capital Analyst forecast on GB:0M0F
Kendall Au
RBC Capital
RBC Capital
$30→$26
Buy
56.16%
Upside
Reiterated
08/06/26
RBC Capital Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
Mizuho Securities Analyst forecast on GB:0M0F
Anthony Petrone
Mizuho Securities
Mizuho Securities
$24→$20
Hold
20.12%
Upside
Reiterated
07/15/26
Tandem Diabetes price target lowered to $20 from $24 at MizuhoTandem Diabetes price target lowered to $20 from $24 at Mizuho
Goldman Sachs Analyst forecast on GB:0M0F
David Roman
Goldman Sachs
Goldman Sachs
$21→$16
Hold
-3.90%
Downside
Reiterated
07/14/26
Tandem Diabetes Care (TNDM) Gets a Hold from Goldman Sachs
Deutsche Bank Analyst forecast on GB:0M0F
Kieran Ryan
Deutsche Bank
Not Ranked
Deutsche Bank
$15.5
Hold
-6.91%
Downside
Initiated
06/23/26
Tandem Diabetes initiated with a Hold at Deutsche BankTandem Diabetes initiated with a Hold at Deutsche Bank
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tandem Diabetes Care

3 Months
Jeff JohnsonRobert W. Baird
Success Rate
10/17 ratings generated profit
59%
Average Return
+55.63%
Copying Jeff Johnson's trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +55.63% per trade.
1 Year
Steven LichtmanWilliam Blair
Success Rate
21/29 ratings generated profit
72%
Average Return
+117.99%
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 72.41% of your transactions generating a profit, with an average return of +117.99% per trade.
2 Years
Jeff JohnsonRobert W. Baird
Success Rate
10/17 ratings generated profit
59%
Average Return
+91.69%
Copying Jeff Johnson's trades and holding each position for 2 Years would result in 58.82% of your transactions generating a profit, with an average return of +91.69% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0M0F Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
4
8
8
8
4
Buy
5
5
4
2
7
Hold
15
10
11
12
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
23
23
22
22
In the current month, 0M0F has received 11 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. 0M0F average Analyst price target in the past 3 months is 26.50.
Each month's total comprises the sum of three months' worth of ratings.

0M0F Financial Forecast

0M0F Earnings Forecast

Next quarter’s earnings estimate for 0M0F is -$0.24 with a range of -$0.36 to -$0.16. The previous quarter’s EPS was -$0.31. 0M0F beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 0M0F has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0M0F is -$0.24 with a range of -$0.36 to -$0.16. The previous quarter’s EPS was -$0.31. 0M0F beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 0M0F has Performed in-line its overall industry.

0M0F Sales Forecast

Next quarter’s sales forecast for 0M0F is $266.06M with a range of $263.00M to $273.90M. The previous quarter’s sales results were $254.14M. 0M0F beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 0M0F has Performed in-line its overall industry.
Next quarter’s sales forecast for 0M0F is $266.06M with a range of $263.00M to $273.90M. The previous quarter’s sales results were $254.14M. 0M0F beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 0M0F has Performed in-line its overall industry.

0M0F Stock Forecast FAQ

What is GB:0M0F’s average 12-month price target, according to analysts?
Based on analyst ratings, Tandem Diabetes Care’s 12-month average price target is 26.50.
    What is GB:0M0F’s upside potential, based on the analysts’ average price target?
    Tandem Diabetes Care has 59.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Tandem Diabetes Care a Buy, Sell or Hold?
          Tandem Diabetes Care has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 7 hold ratings and 0 sell ratings.
            What is Tandem Diabetes Care’s share price target?
            The average share price target for Tandem Diabetes Care is 26.50. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $50.00 ,and the lowest forecast is $15.50. The average share price target represents 59.16% Increase from the current price of $16.65.
              What do analysts say about Tandem Diabetes Care?
              Tandem Diabetes Care’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of Tandem Diabetes Care?
                To buy shares of GB:0M0F, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.